Showing results (691-700 of 963) with videos related to

Sort By:
Pageof 97
The Lancet. Gastroenterology & Hepatology|November 13, 2019
Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trialMan-Fung Yuen, Kosh Agarwal, Edward J Gane, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|April 5, 2011
Efficacy and safety of prolonged 3-year telbivudine treatment in patients with chronic hepatitis BEdward J Gane, Yuming Wang, Yun-Fan Liaw, et al.
JAMA|November 29, 2017
Effect of Oral Capsule- vs Colonoscopy-Delivered Fecal Microbiota Transplantation on Recurrent Clostridium difficile Infection: A Randomized Clinical TrialDina Kao, Brandi Roach, Marisela Silva, et al.
The New England Journal of Medicine|October 12, 2017
Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal ImpairmentEdward Gane, Eric Lawitz, David Pugatch, et al.
European Journal of Pediatrics|March 15, 2020
Energy-dense, low-volume paediatric oral nutritional supplements improve total nutrient intake and increase growth in paediatric patients requiring nutritional support: results of a randomised controlled pilot trialGary P Hubbard, Catherine Fry, Katy Sorensen, et al.
Gastroenterology|March 8, 2014
Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trialXavier Forns, Eric Lawitz, Stefan Zeuzem, et al.
Kidney International Reports|February 19, 2019
Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir in Patients With Hepatitis C Virus Genotype 1 or 4 Infection and Advanced Kidney DiseaseEric Lawitz, Edward Gane, Eric Cohen, et al.
Hepatology (Baltimore, Md.)|April 8, 2015
Sofosbuvir plus pegylated interferon and ribavirin in patients with genotype 1 hepatitis C virus in whom previous therapy with direct-acting antivirals has failedStanislas Pol, Mark S Sulkowski, Tarek Hassanein, et al.
The New England Journal of Medicine|July 1, 2005
Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis BGeorge K K Lau, Teerha Piratvisuth, Kang Xian Luo, et al.
The Lancet. Gastroenterology & Hepatology|October 10, 2024
VIR-2218 (elebsiran) plus pegylated interferon-alfa-2a in participants with chronic hepatitis B virus infection: a phase 2 studyMan-Fung Yuen, Young-Suk Lim, Ki Tae Yoon, et al.
Pageof 97